bluuebunny/crossref_metadata_2025_split huggingface dataset:
10217- NI-17 COMPARISON OF DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION MRI WITH 11C-METHIONINE PET IN ADULT NON-CONTRAST ENHANCED GLIOMAS
Authors: Imai Naoya , Yano Hirohito , Yasuda Shoji , Ikegame Yuka , Kumagai Morio , Shinoda Jun 
Published: November 2024

Abstract

OBJECTIVE
This study examined the correlation between cerebral blood volume (CBV) and MET PET.

SUBJECTS AND METHODS
108 non-contrast-enhanced gliomas (41.8±12.3 years old, 58 males) examined between April 2012 and December 2022 were included. The pathological diagnosis was Glioblastoma, IDH-wildtype (G): 21 cases, Astrocytoma, IDH-mutant (A): 52, Oligodendroglioma, IDH-mutant and 1p/19q codeleted (O): 35. T2 region (the high signal region on T2WI) on MRI and high-MET region (tumor maximum SUV/normal frontal cortex SUV (T/N) ratio &gt; 1.3) on MET PET were defined. The rCBV (regional mean CBV/normal white matter mean CBV) was calculated using dynamic-susceptibility-contrast perfusion MRI to compare each region.

RESULT
The rCBV (3.22±0.95) in the T2 region in 67 patients with MET accumulation was significantly higher than those (2.47±0.64) in 41 patients without MET accumulation (p&lt;0.0001). The cutoff rCBV value obtained from the ROC curve for MET accumulation was 2.79, with a sensitivity of 61.2%, specificity of 75.6%, and AUC of 0.73. The rCBV in the T2 region was (G: 3.60±1.0 A: 2.53±0.69 O: 3.14±0.89) significantly higher in group G (p&lt;0.0001). In the 69 patients with MET accumulation (G: 16, A: 21, O: 30), the rCBV was 3.23±0.96 in the T2 region and 3.48±1.13 in the high-MET region, significantly higher in the latter (p&lt;0.0016). The rCBV was significantly higher in the group G both in the T2 region (G: 3.82±0.97 A: 2.77±0.68 O: 3.22±0.93, p=0.0026) and in the high-MET region (G: 4.12±1.18 A: 3.29±1.0 O: 3.27±1.1, p=0.031). The difference was most in the group A (p=0.016). The rCBV significantly correlated with T/N ratio in both the T2 region (r=0.41, p=0.0005) and the high-MET region (r=0.49, p&lt;0.0001), mainly observed in groups A and O.

DISCUSSION
The rCBV and MET accumulation correlated in non-contrast-enhanced gliomas. The CBV may be an alternative to MET PET in imaging gliomas.
10226- MET-20 PRIMARY UNKNOWN CANCER THAT WAS DIFFICULT TO DIAGNOSE EVEN WITH A CANCER PANEL TEST, PRESENTING AS LEPTOMENINGEAL CARCINOMATOSIS
Authors: Koga Nanako , Yamamoto Etsuko , Matsubara Jyunichi , Takeuchi Yasuhide , Makino Yasuhide , Takada Shigeki , Sano Noritaka , Tanji Masahiro , Mineharu Youhei , Arakawa Yoshiki 
Published: November 2024

Abstract

CASE REPORT
The patient was a 59-year-old male. Three years prior to the current presentation, he developed left peripheral facial nerve palsy. In October of the year before his presentation, his left facial nerve palsy rapidly progressed, and by December, MRI revealed an enhancing lesion in the left cerebellopontine angle, leading to a referral to our hospital. Gadolinium enhanced lesions were located at bilateral cerebellopontine angles, auditory nerves and trigeminal nerves. There were multiple small nodular lesions at cerebellar surface and spinal cord. In March of the current year, the patient underwent biopsy, and the pathological diagnosis was mucinous adenocarcinoma. Despite various examinations, the primary site of the cancer could not be identified. Genetic testing with FoundationOne revealed amplifications of CDK4, MDM2, and ERBB3, along with ATM mutations and STK11 deletions, but a definitive diagnosis was not available. The patient was treated with nivolumab and radiation therapy to the lesion of left cerebellopontine angle, which showed significant enhancement on imaging. While local control was achieved with radiation, the leptomeningeal carcinomatosis progressed, leading to a determination that the disease had progressed. By June of the current year, the patient experienced worsening hearing loss, tinnitus, and back pain due to spinal cord lesions, resulting in a rapid decline in ADL. Radiation therapy was administered for the spinal cord lesions, and the patient passed away about a week later.

DISCUSSION AND CONCLUSION
In this case, despite a pathological diagnosis of mucinous adenocarcinoma, the primary site of the tumor could not be identified. The results from FoundationOne suggested possible origins in the gastrointestinal tract or lung, but a definitive diagnosis was not reached. Molecular diagnostic methods should be developed for difficult-to-diagnose cancers of unknown primary.
10036- MNG-3 EVALUATION OF THE CORRELATION BETWEEN PET STUDIES AND PATHOLOGICAL FINDINGS IN MENINGIOMAS, AND THEIR IMPACT ON RECURRENCE
Authors: Tatano Masaki , Kanda Takahiro , Suzuki Kenta , Ogawa Daisuke , Hatakeyama Tetsuhiro , Miyake Keisuke 
Published: November 2024

Abstract

OBJECTIVE
Meningiomas are the most common primary brain tumors, typically following a benign course. However, some cases recur after surgery, necessitating further treatment or reoperation. This study aims to examine the relationship between PET studies and pathological findings, and their impact on recurrence.

METHODS
We included cases of newly diagnosed meningiomas treated surgically in our department from August 2008 to August 2022. The correlation between preoperative FDG-PET and methionine-PET accumulations with pathological findings (WHO grade, Ki-67 index), as well as the impact on recurrence, was investigated.

RESULTS
The study included 55 cases (22 males, 33 females), aged 17-87 years (median 61.8). The WHO grade was grade 1 in 34 cases and grade 2 in 21 cases, with no grade 3 cases observed. Recurrence occurred in 20 cases during follow-up, necessitating additional treatment. A significant correlation was observed between the tumor T/N ratio and the Ki-67 index for both tracers. Regarding WHO grade, the T/N ratio for FDG was 0.64 in the grade 1 group and 1.04 in the grade 2 group (p&lt;0.01), while for MET, it was 4.8 in the grade 1 group and 6.39 in the grade 2 group (p&lt;0.01), with both tracers showing significantly higher values in the grade 2 group. For postoperative recurrence, the T/N ratio for FDG was 0.97 in the recurrence group and 0.69 in the non-recurrence group (p=0.01), while for MET, it was 6.38 in the recurrence group and 4.66 in the non-recurrence group (p&lt;0.01), with both tracers showing significantly higher values in the recurrence group.

CONCLUSION
The study demonstrated a significant correlation between preoperative PET studies and pathological findings in meningiomas, as well as an association with recurrence. PET studies were significantly correlated with the tumor malignancy and were considered predictors of postoperative recurrence.
10023- COT-4 THE LANDSCAPE OF REGIONAL COLLABORATION OF MEDICAL NETWORK IN SUPPORTIVE CARE FOR BRAIN TUMOR PATIENTS
Authors: Nishiyama Jun , Kanno Mai , Yonemochi Takuya , Sano Fumiya , Nozue Kyoko , Horie Osamu , Ozaki Satoshi , Takahashi Masamichi 
Published: November 2024

Abstract
The physical and mental burden suffers patients and their families in the treatment of malignant brain tumors, which needs close collaboration and intervention by multiple local medical professionals. What both patients and their families want to know is “prognosis,” and healthcare providers need to promptly integrate the information obtained through Advanced Care Planning for patients and their families, identify physical and social problems, and prepare for a quick and smooth transition from core hospital to home health care or local hospital. In our hospital, many professionals participate in the grand conference of Department of Neurosurgery to understand patient’s condition and share goals and challenges interactively. Attending physicians hold ward conferences twice a month with the nurses to share information on the patient’s treatment plan, general condition, discharge issues, and family background. At the same time, while setting a discharge date with the nurses at the patient support center, preparations are made from various angles regarding the patient’s issues and necessary home care support. It should be noted that the attending physician here is also engaged in home health care, enabling close and intimate collaboration between the university hospital and the local community. We report here how we are making a seamless transition from center hospital to community medical network collaboration, based on our clinical experience.
10119- COT-12 ROLE OF GLUCARPIDASE IN DELAYED METHOTREXATE EXCRETION, BASED ON OUR EXPERIENCE
Authors: Tanimura Kazuki , Okada Keiko , Kayatani Rishu , Ueda Kazuhiro , Matsuoka Yuki , Yamasaki Kai , Nitani Chika , Fujisaki Hiroyuki , Hara Junichi 
Published: November 2024

Abstract

INTRODUCTION
High-dose methotrexate (HD-MTX) is widely used to treat primary central nervous system lymphomas and medulloblastoma in infants. A key problem associated with this regimen is slow elimination, which can rapidly cause renal and hepatic damage. Glucarpidase was launched in January 2024 as a treatment for delayed elimination, but to date no guidelines have been established for its administration in Japan. Thus, we retrospectively examined data from cases of glucarpidase use in our department, including patients enrolled in the clinical trial.

PATIENTS AND METHODS
This study included 14 patients (10 males and four females) who received glucarpidase to counter delayed elimination during HD-MTX therapy between January 2015 and July 2024.

RESULTS
Median patient age was 7.5 years (range: 1.5-79 years) and the treated disease was acute leukemia in seven patients, lymphoma in four, osteosarcoma in two, and medulloblastoma in one. During glucarpidase administration, seven patients were experiencing renal impairment and three had elevated hepatic enzyme levels. The median blood MTX concentration at the first dose of glucarpidase was 4.9 μM (range: 1.02-24.1 μM). This decreased to 0.22 μM (range: 0.07-1.66 μM) at 48 h post-administration. Glucarpitase was re-administered in one patient. Median time to &lt;0.2 μM was 96 h (range: 24-336 h). Peak renal impairment occurred at a median of 24 h (range: 0-96 h), and median time to normalization was 456 h (range: 96-648 h). Six of 12 patients were re-treated with HD-MTX. Four of these showed delayed elimination but did not require glucarpidase re-administration.

DISCUSSION
This study confirmed the efficacy and safety of glucuronidase for delayed elimination during HD-MTX therapy in real-world clinical practice. Timely detection of delayed elimination and examination of the indications for this agent are important to improve HD-MTX therapy safety.
10203- COT-21 DIFFERENCES IN THE RISK OF BRAIN TUMOR OCURRENCE ACCORDING TO REGIONAL DIFFERENCES AND EMPLOYMENT HISTORY
Authors: Murakami Tomoaki , Toyota Shingo , Achiha Takamune , Okochi Kosei , Nakashima Koichi , Okuhara Shuki , Tohara Kazuhiro , Yamada Shuhei , Kobayashi Maki 
Published: November 2024

Abstract
We investigated the relationship between occupational history and regional differences in the risk of brain tumor occurrence using the Inpatient Clinico-Occupational Database of the Rosai Hospital Group. 8546 patients hospitalised with primary brain/spinal cord tumors excluding metastatic brain/spinal cord tumors from 1996 to 2021 at the Rosai Hospital Group were included. Patients were divided into two groups: ICD codes for ‘malignant’ tumors (malignant group) and benign and other ICD codes (non-malignant group), and patient backgrounds, occupational classification (current occupation) and regional characteristics were compared. 2448 patients in the malignant group and 6098 patients in the non-malignant group. Comparing the patient backgrounds of the two groups, the age at admission was higher in the malignant group and the proportion of women was higher in the non-malignant group. There was no correlation with history of smoking, alcohol and medical history. With regard to the proportion of occupational categories (current occupation) in each group, Agricultural workers were significantly more in the malignant group. (P=0.0001, Odds ratio: 1.820; 1.328 to 2.488) Also, regarding regional differences, in the majority of regions the non-malignant group had approximately 1.2-2.5 times as many cases as the malignant group, while in the Kanto region the non-malignant group had approximately five times as many cases as the malignant group (2618 vs 518, p&lt;0.0001)The present study suggests an association between agricultural workers and the malignant group. Although there have been previous reports on the association between agricultural workers and brain tumours, none have noted an association between agricultural workers and ‘malignant’ brain/spinal cord tumours. With regard to regional characteristics, the number of cases in the non-malignant group was overwhelmingly higher in the Kanto region. This could be due to differences in the number of hospitals, characteristics between hospitals, surgeons, MRI coverage and asymptomatic lesion detection rates.
IL-6 RESEARCH INTO INTRACTABLE CANCER AIMING FOR IMPLEMENTATION
Authors: Saya Hideyuki 
Published: November 2024

Abstract
Many people believe that “excellent basic research results will inevitably lead to practical applications,” but this is not necessarily true. Although it is undeniable that the drugs and medical devices that have been put into practice are the result of excellent research, having excellent research does not guarantee that it will be put into practice. There are countless research seeds that disappear without being implemented. In other words, bridging the gap between basic research and application is as challenging as building a bridge over a turbulent river, and it is not a problem that can be solved by academics and scientists alone. Translational research requires more than just academic rigor. It also involves addressing regulatory and intellectual property issues, securing funding, procuring necessary materials, and most importantly, assembling specialized personnel and support staff to drive the project forward. Bringing all these resources together is no easy feat. Drug discovery and medical device development once took place in large corporations, but as medical science has become more complex, development has shifted entirely to academia. This reality highlights the challenges of creating new medicines, but also the opportunity to solve even the smallest clinical problems (needs) yourself. In this educational talk, I will explore the importance and strategies for translating insights from basic research and clinical practice into practical applications, drawing from my own experience.
A systematic review and meta-analysis of the efficacy and safety of traditional Chinese medicine in the treatment of rhinosinusitis
Authors: Huang Zhihao , Xuan Xin , Liu Shan , Lin Jinglan , Qian Zhijun , Chen Lifen , Qiu Ruoqing , Cai Yanwen 
Published: November 2024

Background:
Rhinosinusitis (RS), a common inflammatory disorder, adversely affects quality of life and can progress to serious complications without intervention. Conventional therapies, including antibiotics and corticosteroids, exhibit inherent limitations and risks. Traditional Chinese medicine (TCM), with its extensive historical use in RS management, remains understudied in contemporary evaluations. This systematic review evaluates the efficacy and safety of TCM in RS treatment, aiming to guide clinical decision-making.

Methods:
A systematic search was undertaken in Chinese and English databases, such as CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, Web of Science, and other relevant databases, to gather randomized controlled trials of TCM for patients with RS from January 2014 to February 2024. Two researchers independently curated and synthesized data from eligible literature, conducted meta-analyses with ReviewManager 5.4.1, and assessed evidence quality via GRADEPro GDT.

Results:
A total of 48 articles included 4490 patients, of which 2249 were control group and 2241 were in the experimental group. Meta-analytic outcomes revealed that the integration of TCM with western medicine conventional treatment significantly enhanced the total effective rate [risk ratio=1.20, 95% confidence interval (CI) (1.17, 1.23), P < 0.05] and yielded a notable reduction in Lund–Kennedy score [mean difference (MD)=−1.32, 95% CI (−1.72, −0.93), P < 0.05], Lund–Mackay score [MD=−1.13, 95% CI (−1.27, −1.00), P < 0.05], SNOT-20 score [MD=−3.02, 95% CI (−4.34, −1.69), P < 0.05], nasal congestion Visual Analogue Scale (VAS) score [MD=−1.05, 95% CI (−1.65, −0.45), P < 0.05], runny nose VAS score [MD=−0.84, 95% CI (−1.13, −0.54), P < 0.05], headache VAS score [MD=−0.90, 95% CI (−1.45, −0.35), P < 0.05], olfactory impairment VAS score [MD=−1.43, 95% CI (−1.75, −1.11), P < 0.05], and total TCM syndrome score [standardized mean difference (SMD)=−1.78, 95% CI (−2.58, −0.97), P < 0.05]. Additionally, significant decreases were observed in levels of tumor necrosis factor-α [SMD=−2.14, 95% CI (−3.42, −0.87), P < 0.05] and interleukin-6 [SMD=−1.64, 95% CI (−2.08, −1.21), P < 0.05], with statistical significance achieved for all measured outcomes. Regarding safety considerations, an insignificant variance was observed between the 2 therapeutic approaches, with no statistically discernible difference (P > 0.05).

Conclusion:
Combining TCM with western medicine in RS treatment yields superior outcomes over western medicine alone, with enhanced efficacy, reduced nasal symptoms, and lower inflammation. Rigorous multicenter RCTs are warranted to affirm these advantages and bolster the evidence for TCM in RS management.
Analysis of the efficacy of two kinds of loss restoration of posterior teeth using 3D printing temporary crown during the second phase of implant surgery
Authors: Cao Yannan , Hu Meichun , Zhang JinLin , Yu Liuping , Gao Yufeng , Ding Zhuang , Ma Hong , Zhu Fangyong 
Published: November 2024

Background:
This study aimed to analyze the effect of 3D printing temporary crowns on the single and continuous loss restoration of posterior teeth during secondary implant surgery.

Methods:
This study adopted a single-center, randomized, single-blind, parallel-controlled trial design. Thirty patients who were admitted to the Department of Stomatology, Affiliated Hospital of Jiangnan University between January 2020 and February 2023 and who had >2 consecutive missing posterior teeth were implanted with the same implant system. A simple random method was adopted to assign 30 patients to group A (using 3D-printed temporary crowns) and group B (control group) in a 1:1 ratio, with 15 patients in each group. The final prosthesis in Experimental group A was done based on the adjustment of the temporary crown and tooth. Both groups were compared based on total time, accuracy, and patient satisfaction of the final prosthesis. Additionally, 30 patients who had undergone single posterior tooth implantation during the same period were selected as the study objects and divided into 2 groups using the random comparison table method. The patients in the experimental group C (15 cases) were provided with 3D-printed temporary crowns, and the other 15 patients were assigned to the control group D (15 cases).

Results:
In the experimental group A, the total time spent on dentures was 10.1 ± 1.3 minutes, which was lesser compared with that spent in the control group B (P < .05). Experimental group A exhibited a significantly higher accuracy of prosthesis (P < .05), as well as significantly higher satisfaction of patients (P < .05). Regarding the food impaction rate, after formal implantation and restoration, the food impaction rate of the experimental group C at 1 month and 6 months was compared with that of the traditional 2-stage surgery group D.

Conclusion:
Three-dimensional printing temporary crowns exhibited significantly better therapeutic effects for restoration in patients with continuous missing implants in posterior teeth. 3D printing temporary crowns in patients with single posterior tooth implant restoration showed promising results, which improved food immobilization and actively and effectively reduced the complications associated with a single posterior tooth implant.
A new nonsense mutation of PTCH1 gene in mother and daughter with late-onset nevus basal cell carcinoma syndrome: Case report
Authors: Li Xin , Ai Liya , Han Chun-Yu , Cao Ya-Qi , Han Jian-Wen 
Published: November 2024

Rationale:
Nevoid basal cell carcinoma syndrome (NBCCS) is a rare clinical disease characterized by a disproportionate number of basal cell carcinoma to sun exposure and skin types. Patched 1 (PTCH1) gene is proposed to be implicated in the pathogenesis of NBCCS. This study aimed to investigate whether PTCH1 gene is the causative gene in Chinese patients with NBCCS.

Patient concerns:
Here we detected the first nonsense mutation in PTCH1 gene by Sanger sequencing of blood samples from a mother and her second daughter (NM000264: exon14: c.2080C>T: p.Q694X).

Diagnoses:
Both of the mother and her second daughter had ovarian mature teratomas.

Interventions:
The mother received liquid nitrogen cryotherapy, surgical resection, and radiation therapy, while her second daughter was treated with a GX-III multifunctional ion surgical therapy machine and surgery.

Outcomes:
New rashes continued to appear and contractures of the right eyelid healed in the mother, while her second daughter had multiple pitting depressions on the palms and soles of both hands and feet.

Conclusion:
We detected a new mutation in PTCH1 gene in 2 patients with NBCCS, and both of them had ovarian mature teratomas, which are related to NM000264: exon14: c.2080C>T: p.Q694X.
Early use of low-dose hydrocortisone can reduce in-hospital mortality in patients with septic shock: A systematic review and meta-analysis
Authors: Song Binglin , Zheng Xiangde , Fu Kangrui , Liu Chun 
Published: November 2024

Background:
This study aimed to assess the impact of the timing of low-dose hydrocortisone adjuvant therapy initiation on clinical outcomes in patients with septic shock by a systematic review and meta-analysis.

Methods:
We conducted a comprehensive search of all randomized controlled trials (RCTs) and cohort studies available in the PubMed, Web of Science, and Embase databases. The search included articles published from the founding of these databases until August 1, 2024. The purpose of the search was to compare the results of initiating low-dose hydrocortisone (HC) adjuvant therapy at different time periods. The main reported results included short-term mortality (ICU mortality and hospital mortality) as key outcomes, and secondary outcomes such as the rate of renal replacement treatment continuous renal replacement therapy (CRRT), length of stay in the intensive care unit (ICU), and rate of shock reversal.

Results:
Seven trials, with a total of 3063 patients, were included. The main finding of this meta-analysis indicates that the early treatment group, which received low-dose hydrocortisone, had a lower ICU mortality rate compared to the late treatment group. Additionally, the hospital mortality rate in the early treatment group was lower than that in the late treatment group. There was a correlation between the timing of beginning of HC and the short-term mortality of patients with septic shock. The secondary findings indicated that there were no notable disparities in the rates of CRRT, the rate of reversing shock, and the duration of stay in the ICU.

Conclusion:
Administering low doses of HC early on can decrease the risk of death in septic shock patients in the short-term mortality. There were no substantial disparities observed in the rate of CRRT, the rate of reversal of shock, and the duration of stay in the ICU. Additional extensive RCTs are required to validate this conclusion.